Equity in the Receipt of Oseltamivir in the United States During the H1N1 Pandemic

Franklin, Jessica Myers; Choudhry, Niteesh Kumar; Uscher-Pines, Lori; Brill, Gregory; Matlin, Olga S.; Fischer, Michael Adam; Schneeweiss, Sebastian; Avorn, Jerry Lewis; Brennan, Troyen Anthony; Shrank, William

View/Open

202366/2014_tamiflu_trends_ajph.pdf (583.9Kb)

Access Status

Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.

Author

Franklin, Jessica Myers HARVARD

Choudhry, Niteesh Kumar HARVARD

Uscher-Pines, Lori

Brill, Gregory

Matlin, Olga S.

Fischer, Michael Adam HARVARD

Schneeweiss, Sebastian HARVARD

Avorn, Jerry Lewis HARVARD

Brennan, Troyen Anthony HARVARD

Shrank, William HARVARD

Published Version

https://doi.org/10.2105/AJPH.2013.301762

Metadata

Show full item record

Citation

Franklin, Jessica M., Niteesh K. Choudhry, Lori Uscher-Pines, Gregory Brill, Olga S. Matlin, Michael A. Fischer, Sebastian Schneeweiss, Jerry Avorn, Troyen A. Brennan, and William H. Shrank. 2014. “Equity in the Receipt of Oseltamivir in the United States During the H1N1 Pandemic.” American Journal of Public Health 104 (6) (June): 1052–1058. doi:10.2105/ajph.2013.301762.

Abstract

Objectives. We assessed the relationship between individual characteristics and receipt of oseltamivir (Tamiflu) in the United States during the H1N1 pandemic and other flu seasons.
Methods. In a cohort of individuals enrolled in pharmacy benefit plans, we used a multivariate logistic regression model to measure associations between subscriber characteristics and filling a prescription for oseltamivir during 3 flu seasons (October 2006–May 2007, October 2007–May 2008, and October 2008–May 2010). In 19 states with county-level influenza rates reported, we controlled for disease burden.
Results. Approximately 56 million subscribers throughout the United States were included in 1 or more study periods. During pandemic flu, beneficiaries in the highest income category had 97% greater odds of receiving oseltamivir than those in the lowest category (P < .001). After we controlled for disease burden, subscribers in the 2 highest income categories had 2.18 and 1.72 times the odds of receiving oseltamivir compared with those in the lowest category (P < .001 for both).
Conclusions. Income was a stronger predictor of oseltamivir receipt than prevalence of influenza. These findings corroborate concerns about equity of treatment in pandemics, and they call for improved approaches to distributing potentially life-saving treatments.